Theophylline ER — Membership Pricing

Other medications in Respiratory

• Tiotropium
• Treprostinil Oral
• Zafirlukast
• Zileuton
• Albuterol
• Budesonide
• Cromolyn Sodium Inhaler
• Fluticasone

What Theophylline ER is approved for (FDA label)

Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis.

Source: Read the full FDA label on DailyMed. Label effective date: July 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Theophylline ER (FDA label)

: Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are <20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as nausea, vomiting, headache, and insomnia. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including persistent vomiting, cardiac arrhythmias, and intractable seizures which can be lethal (see OVERDOSAGE ). The transient caffeine-like adverse reactions occur in about 50% of patients when theophylline therapy is initiated at doses higher than recommended initial doses (e.g., >300 mg/day in adults and >12 mg/kg/day in children beyond >1 year of age).

Source: FDA prescribing information (DailyMed). Set ID: 5e64036a-ee3e-42e7-9e59-881f88a4e298. SPL document ID: 57c5cb6d-297f-7b7c-e063-6294a90a93a9. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Theophylline ER (FDA label)

Theophylline extended-release tablets are contraindicated in patients with a history of hypersensitivity to theophylline or other components in the product.

Source: FDA prescribing information (DailyMed). Set ID: 5e64036a-ee3e-42e7-9e59-881f88a4e298. SPL document ID: 57c5cb6d-297f-7b7c-e063-6294a90a93a9. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Theophylline ER (FDA label)

Drug-Drug Interactions: Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs. The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or pharmacokinetic interactions with theophylline. The information in the "Effect" column of Table II assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller.

Source: FDA prescribing information (DailyMed). Set ID: 5e64036a-ee3e-42e7-9e59-881f88a4e298. SPL document ID: 57c5cb6d-297f-7b7c-e063-6294a90a93a9. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.